Alternative therapies for drug refractory B cell malignancies are urgently needed. We used advances last cycle to develop a new class of recombinant bispecific targeted toxin with expanded ability to recognize a wider range of B cell cancers. With funding from this grant, we discovered that bispecific targeted toxins could be made by fusing two repeating scFv subunits creating a bispecific ligand directed toxin and they had superior activity over monospecific targeted toxins. We brought the drug to clinical trial for leukemia. Findings are encouraging, but preliminary data indicates that toxin immunogenicity will be a problem as anticipated. Multiple dosing is required to obtain sustained remissions and this generates anti-toxin antibodies that impact drug efficacy. To this end, we have found an important new and successful way to deimmunize our toxin that may have implications for deimmunizing other molecules.
In aim 1, we propose to study this deimmunization. Funding from this proposal has also led to the development of a very different targeted toxin that has the ability to target cancer stem cells. Current theory dictates that cancer cells differentiate as do normal cells. The cancer cell population consists of a small cohort of less differentiated, self renewing, tumor initiating stem cells and a larger cohort of more differentiated tumor cells. More differentiated cells are more susceptible to chemotherapy and the minor fraction of less differentiated cancer stem cells are more drug resistant, thus contributing to drug refractory relapse in cancer. We have created a new targeted toxin that targets cancer stem cells and clearly has therapeutic efficacy in systemic mouse models of cancer. The agent has the advantage of working against a variety of different cancers.
In aim 2, we propose to study this new strategy of targeting tumor stem cells.
Aim 1 relates to Aim 2 since the deimmunization strategies are used to construct anti-stem cell targeted toxins as well.

Public Health Relevance

Our group has discovered a new class of biological drugs called bispecific targeted toxins that show superiority over their monospecific counterparts and can be genetically modified to address some of the major problems in the field and we have proven that multiple treatments with these drugs are highly effective against systemic cancer in animals resulting in long-term disease free survivors. In this proposal, we will be addressing some of the major issues with these drugs. We will be investigating improvements in reducing their immunogenicity and destroying the most important drug resistant cells, cancer stem cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA036725-28
Application #
8454558
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Welch, Anthony R
Project Start
1984-01-01
Project End
2016-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
28
Fiscal Year
2013
Total Cost
$224,211
Indirect Cost
$75,727
Name
University of Minnesota Twin Cities
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Gleason, Michelle K; Ross, Julie A; Warlick, Erica D et al. (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123:3016-26
Skubitz, Amy P N; Taras, Elizabeth P; Boylan, Kristin L M et al. (2013) Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol 130:579-87
Schappa, Jill T; Frantz, Aric M; Gorden, Brandi H et al. (2013) Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors. Int J Cancer 133:1936-44
Oh, Seunguk; Todhunter, Deborah A; Panoskaltsis-Mortari, Angela et al. (2012) A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model. Pancreas 41:789-96
Waldron, Nate N; Kaufman, Dan S; Oh, Seunguk et al. (2011) Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol Cancer Ther 10:1829-38
Tsai, Alexander K; Oh, Seunguk; Chen, Hua et al. (2011) A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neurooncol 103:255-66
Oh, Seunguk; Tsai, Alexander K; Ohlfest, John R et al. (2011) Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain. J Neurosurg 114:1662-71
Oh, Seunguk; Stish, Brad J; Vickers, Selwyn M et al. (2010) A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. Pancreas 39:913-22
Vallera, Daniel A; Oh, Seunguk; Chen, Hua et al. (2010) Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther 9:1872-83
Oh, Seunguk; Stish, Brad J; Sachdev, Deepali et al. (2009) A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res 15:6137-47

Showing the most recent 10 out of 69 publications